Yen, T.-H.; Tseng, C.-W.; Wang, K.-L.; Fu, P.-K.
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina 2021, 57, 1358.
https://doi.org/10.3390/medicina57121358
AMA Style
Yen T-H, Tseng C-W, Wang K-L, Fu P-K.
Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina. 2021; 57(12):1358.
https://doi.org/10.3390/medicina57121358
Chicago/Turabian Style
Yen, Tsai-Hung, Chih-Wei Tseng, Kao-Lun Wang, and Pin-Kuei Fu.
2021. "Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report" Medicina 57, no. 12: 1358.
https://doi.org/10.3390/medicina57121358
APA Style
Yen, T.-H., Tseng, C.-W., Wang, K.-L., & Fu, P.-K.
(2021). Combination Therapy with Rituximab, Tofacitinib and Pirfenidone in a Patient with Rapid Progressive Interstitial Lung Disease (RP-ILD) Due to MDA5 Antibody-Associated Dermatomyositis: A Case Report. Medicina, 57(12), 1358.
https://doi.org/10.3390/medicina57121358